Wednesday, August 26, 2015
Kiadis Pharma BV Reports H1 net loss of 9.6 million euros ($11.09 million) versus loss of 3.5 million euros a year ago.
H1 operating loss is 11.7 million euros versus loss of 2.9 million euros a year ago.
Says cash at June 30, 2015 was 2.5 million euros versus 3.6 million euros at end of June 30, 2014.
Says make good progress with phase II clinical trial using ATIR101 and remain on track .
reuters.com
